Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

  1. Herold, Tobias ORCID logo
  2. Rothenberg-Thurley, Maja
  3. Grunwald, Victoria V.
  4. Janke, Hanna
  5. Goerlich, Dennis
  6. Sauerland, Maria C.
  7. Konstandin, Nikola P.
  8. Dufour, Annika
  9. Schneider, Stephanie
  10. Neusser, Michaela
  11. Ksienzyk, Bianka
  12. Greif, Philipp A.
  13. Subklewe, Marion
  14. Faldum, Andreas
  15. Bohlander, Stefan ORCID logo
  16. Braess, Jan
  17. Wörmann, Bernhard
  18. Krug, Utz
  19. Berdel, Wolfgang E.
  20. Hiddemann, Wolfgang
  21. Spiekermann, Karsten
  22. Metzeler, Klaus ORCID logo

Download
s41375-020-0806-0.pdf 2,29MB
WeightNameValue
1000 Titel
  • Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
1000 Autor/in
  1. Herold, Tobias |
  2. Rothenberg-Thurley, Maja |
  3. Grunwald, Victoria V. |
  4. Janke, Hanna |
  5. Goerlich, Dennis |
  6. Sauerland, Maria C. |
  7. Konstandin, Nikola P. |
  8. Dufour, Annika |
  9. Schneider, Stephanie |
  10. Neusser, Michaela |
  11. Ksienzyk, Bianka |
  12. Greif, Philipp A. |
  13. Subklewe, Marion |
  14. Faldum, Andreas |
  15. Bohlander, Stefan |
  16. Braess, Jan |
  17. Wörmann, Bernhard |
  18. Krug, Utz |
  19. Berdel, Wolfgang E. |
  20. Hiddemann, Wolfgang |
  21. Spiekermann, Karsten |
  22. Metzeler, Klaus |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-03-30
1000 Erschienen in
1000 Quellenangabe
  • 34(12):3161-3172
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41375-020-0806-0 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685975/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification of acute myeloid leukemia have been widely adopted, but have not yet been validated in large cohorts of AML patients. We studied 1116 newly diagnosed AML patients (age range, 18-86 years) who had received induction chemotherapy. Among 771 patients not selected by genetics, the ELN-2017 classification re-assigned 26.5% of patients into a more favorable or, more commonly, a more adverse-risk group compared with the ELN-2010 recommendations. Forty percent of the cohort, and 51% of patients ≥60 years, were classified as adverse-risk by ELN-2017. In 599 patients <60 years, estimated 5-year overall survival (OS) was 64% for ELN-2017 favorable, 42% for intermediate-risk and 20% for adverse-risk patients. Among 517 patients aged ≥60 years, corresponding 5-year OS rates were 37, 16, and 6%. Patients with biallelic CEBPA mutations or inv(16) had particularly favorable outcomes, while patients with mutated TP53 and a complex karyotype had especially poor prognosis. DNMT3A mutations associated with inferior OS within each ELN-2017 risk group. Our results validate the prognostic significance of the revised ELN-2017 risk classification in AML patients receiving induction chemotherapy across a broad age range. Further refinement of the ELN-2017 risk classification is possible.
1000 Sacherschließung
lokal Mutation/genetics [MeSH]
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Acute myeloid leukaemia
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Middle Aged [MeSH]
lokal Risk Factors [MeSH]
lokal Induction Chemotherapy/methods [MeSH]
lokal Risk factors
lokal Translational research
lokal Genetics research
lokal Survival Rate [MeSH]
lokal Article
lokal Male [MeSH]
lokal Leukemia, Myeloid, Acute/genetics [MeSH]
lokal Cancer genetics
lokal Prognosis [MeSH]
lokal Young Adult [MeSH]
lokal Risk Assessment/methods [MeSH]
lokal Leukemia, Myeloid, Acute/pathology [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-9615-9432|https://frl.publisso.de/adhoc/uri/Um90aGVuYmVyZy1UaHVybGV5LCBNYWph|https://frl.publisso.de/adhoc/uri/R3J1bndhbGQsIFZpY3RvcmlhIFYu|https://frl.publisso.de/adhoc/uri/SmFua2UsIEhhbm5h|https://frl.publisso.de/adhoc/uri/R29lcmxpY2gsIERlbm5pcw==|https://frl.publisso.de/adhoc/uri/U2F1ZXJsYW5kLCBNYXJpYSBDLg==|https://frl.publisso.de/adhoc/uri/S29uc3RhbmRpbiwgTmlrb2xhIFAu|https://frl.publisso.de/adhoc/uri/RHVmb3VyLCBBbm5pa2E=|https://frl.publisso.de/adhoc/uri/U2NobmVpZGVyLCBTdGVwaGFuaWU=|https://frl.publisso.de/adhoc/uri/TmV1c3NlciwgTWljaGFlbGE=|https://frl.publisso.de/adhoc/uri/S3NpZW56eWssIEJpYW5rYQ==|https://frl.publisso.de/adhoc/uri/R3JlaWYsIFBoaWxpcHAgQS4=|https://frl.publisso.de/adhoc/uri/U3Via2xld2UsIE1hcmlvbg==|https://frl.publisso.de/adhoc/uri/RmFsZHVtLCBBbmRyZWFz|https://orcid.org/0000-0002-2202-9088|https://frl.publisso.de/adhoc/uri/QnJhZXNzLCBKYW4=|https://frl.publisso.de/adhoc/uri/V8O2cm1hbm4sIEJlcm5oYXJk|https://frl.publisso.de/adhoc/uri/S3J1ZywgVXR6|https://frl.publisso.de/adhoc/uri/QmVyZGVsLCBXb2xmZ2FuZyBFLg==|https://frl.publisso.de/adhoc/uri/SGlkZGVtYW5uLCBXb2xmZ2FuZw==|https://frl.publisso.de/adhoc/uri/U3BpZWtlcm1hbm4sIEthcnN0ZW4=|https://orcid.org/0000-0003-3920-7490
1000 Hinweis
  • DeepGreen-ID: ae1588d6861b456dbd3ec9f52fd46cf6 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6471034.rdf
1000 Erstellt am 2023-11-18T10:27:01.407+0100
1000 Erstellt von 322
1000 beschreibt frl:6471034
1000 Zuletzt bearbeitet 2023-12-01T13:32:39.357+0100
1000 Objekt bearb. Fri Dec 01 13:32:39 CET 2023
1000 Vgl. frl:6471034
1000 Oai Id
  1. oai:frl.publisso.de:frl:6471034 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source